NorthStrive Biosciences, a subsidiary of PMGC Holdings Inc., announced the start of Phase III of its AI Development Program in collaboration with Yuva Biosciences. This phase advances compounds identified through earlier AI‑guided screening toward experimental validation, marking a key step in progressing its pipeline of potential therapies addressing obesity and related metabolic conditions.
Under the Development and License Agreement with YuvaBio, the Phase III work builds on Phase II results in which YuvaBio’s proprietary MitoNova™ artificial intelligence platform prioritized small‑molecule candidates with predicted benefits for mitochondrial health and muscle preservation. These factors are considered important for metabolic function, particularly in the context of weight‑loss therapies where muscle integrity can be compromised.
Phase III will involve generating meaningful biological data on the AI‑selected compounds, including cytotoxicity screening and expression testing of ANT1, a gene linked to mitochondrial function and metabolic health. This experimental validation aims to confirm computational predictions and narrow the list of compounds for further development. The work is expected to take several weeks to months as laboratory results are gathered.
According to the company, advancing to Phase III reflects progress in integrating machine‑learning methodologies with experimental science to accelerate drug discovery and improve the efficiency of identifying therapeutic candidates that may support muscle preservation and metabolic outcomes.
NorthStrive continues to operate under PMGC Holdings’ broader biopharmaceutical strategy while exploring innovative approaches to tackle complex metabolic and obesity‑related disorders through AI‑powered discovery.
